A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis

Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Study ID
NCT07598383
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VC005 group — DRUG
    VC005 group with Local topical application
  • VC005 Placebo group — DRUG
    VC005 Placebo group with Local topical application

Study Details

This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis

Key Dates

First listed
May 20, 2026
Start date
Jun 1, 2026
Status verified
Jul 2026
Primary completion
Feb 22, 2027
Completion
Feb 22, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: VC005 Dose A group
  • Experimental: VC005 Dose B group
  • Experimental: VC005 Dose C group
  • Placebo Comparator: VC005 Placebo group

Primary Outcome Measure

Changes in EASI（Eczema area and severity index） from baseline [ Time Frame: Week 4 ]

Central Contacts

Find similar trials

Nationwide
Atopic dermatitis / eczema trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies